Evidence supports modest improvements in skin firmness, elasticity, and fine lines over 812 weeks of consistent use
Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [60]
While Zepbound has demonstrated greater weight loss results, both medications are effective in helping with weight management, especially when combined with diet and exercise
doi: 10.1562/0031-8655(2000)072 2.0.co;2
SubQ daily enables smaller, more frequent amounts with the ability to increase after the first week, depending on clinical direction